A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Inclusion Criteria

• •Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
• •Are being treated with or initiating Raptiva therapy at the time of enrollment
• •Be able to provide written informed consent
• •Be willing and able to fully to participate for the duration of patient follow-up (5 years)
• •Exclusion Criterion:
• •Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment